ACE inhibitors have become an essential component in the treatment of heart failure. But is low-dose ACE inhibitor therapy as effective as high-dose ACE inhibitor therapy in this indication? This question was addressed at the 47th Annual Scientific Sessions of the American College of Cardiology [Atlanta, US; March 1998], where the results of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial were presented.